Showing results (341-350 of 395) with videos related to

Sort By:
Pageof 40
The Journal of Infectious Diseases|September 17, 2011
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adultsJeffrey S Kennedy, Marc Gurwith, Cornelia L Dekker, et al.
Vaccine|January 24, 2021
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and olderPatricia Winokur, Hana M El Sahly, Mark J Mulligan, et al.
Plos One|March 26, 2013
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humansJohn Lok Man Law, Chao Chen, Jason Wong, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|September 8, 2020
Identification of the Physiologically Difficult Airway in the Pediatric Emergency DepartmentPreston N Dean, Erin F Hoehn, Gary L Geis, et al.
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
The Journal of Infectious Diseases|October 29, 2010
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesSamer S El-Kamary, Marcela F Pasetti, Paul M Mendelman, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
Vaccine|July 13, 2010
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsSharon E Frey, Michael Houghton, Stephen Coates, et al.
The Journal of Infectious Diseases|July 23, 2016
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster VaccinationDaniel F Hoft, Kathleen Lottenbach, Johannes B Goll, et al.
Vaccine|May 14, 2013
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenarioSharon E Frey, Patricia L Winokur, Robert A Salata, et al.
Pageof 40